1 and 225 nontransplant recipients (GNB n = 114; SAB n =
111)
were included for clinical analysis.
2 that were accrued from January 1, 2010 to October 1,
2017,
were included in this retrospective study.
3 ated between Sept 7, 2016, and Aug 18, 2017; 19 021 (94.
6%)
were included in the per protocol analysis, and 20 071 (99.9%
4 ), severe NPDR (n = 20), and proliferative DR (PDR; n =
72)
were included.
5 randomized (mean age, 68 years; 181 [55%] women), 320 (
97%)
were included in the primary outcome analysis.
6 tudies (3377 patients) from Asia, Europe, and North
America were included (14 of 34 adult studies included only hospitali
7 centers in the United States were treated with axi-cel
and were included in a modified intent-to-treat (mITT) analysis.
8 r than 90% "critical" and less than 15% "not important"
and were included in the final PICU core outcome set: four Global
9 A total of 39
articles were included in the meta-analysis.
10 Eighty-one
articles were included in this review, of which 12 were randomized cli
11 criminate extant taxa from extinct species when adult
birds were included.
12 ed and 11 636 participants (7548 in the UK, 4088 in
Brazil)
were included in the interim primary efficacy analysis.
13 ns in adults, whether administered alone or as care
bundles were included in the analyses.
14 < 296 dB/m, BMI < 25 kg/m(2) and normal waist
circumference were included in the interventional analysis.
15 In total, 485 HEU children and 2495 HIV-unexposed
controls were included.
16 F-FET PET (time after surgery: median, 14 d; range, 5-28
d)
were included.
17 t were electively admitted for gastrointestinal
endoscopies were included.
18 A total of 263,480
eyes were included, with mean age 71.4 +/- 11.7 years.
19 erified primary or secondary lymphoma of the lacrimal
gland were included.
20 A total of 72
infants were included in the study.
21 From 2012-2015, 203 patients with suspected CNS
infections were included, of whom 56 (27%) were diagnosed with CNS infec
22 ostprandial GLP-1, postprandial PYY, and fasting GIP
levels were included.
23 and were receiving at least 2 antihypertensive
medications were included.
24 0 +/- 18.0 years and mean follow-up of 78.6 +/- 42.2
months were included.
25 edian mean deviation, -2.31 dB) and 65 control
participants were included in the study.
26 facially disfigured and 74 facially disfigured
participants were included.
27 nd 33 cohort studies, with a total of 179 230
participants,
were included.
28 216 066
patients were included.
29 A total of 111
patients were included: 64 full germline, familial patients (53 HP and
30 excluded from efficacy analyses; the remaining 151
patients were included in the per-protocol efficacy analyses.
31 Forty-seven eyes from 24
patients were included in this study.
32 the group with ITBA (n = 10 of 35; 28.6%), and 25
patients were included in the group without ITBA.
33 A total of 1 511 602
patients were included in this study: 24 892 OAG patients and 1 484 79
34 A total of 102 eyes of 63
patients were included in this study.
35 A total of 6632
patients were included; at baseline, 3352 (50.5%) did not have diureti
36 Two hundred eighty-five
patients were included with a median follow-up was 5.8 years.
37 Results Three hundred thirty-four
patients were included (mean age, 55 years +/- 11 [standard deviation]
38 1035 HCV-infected
patients were included, 667 (64%) coinfected with HIV.
39 Ten
patients were included in the group with ITBA (n = 10 of 35; 28.6%), a
40 Results: (18)F-NaF PET/CT scans from 219 patients with
PCa were included, of whom 129 patients were scanned for primary
41 associated with >= 6 mm residual probing pocket depth (
PPD)
were included and randomly assigned to one of three groups: A
42 etrospective studies, prospective analyses, and case
series were included.
43 sthma and the European Community Respiratory Health
Survey)
were included.
44 to the 23 at 3 hospitals within the Northwell Health
system were included in this prospective, observational study.
45 Of the 164 patients
that were included in the analysis, 57 patients received liposomal
46 apy as well as studies examining strategies to improve
this were included.
47 s and 2 clinical visits with Goldmann applanation
tonometry were included.
48 olid malignancies and an indication for sorafenib
treatment were included.
49 Five
trials were included; follow-up duration ranged from 12 to 15 months
50 In total, 470,646
women were included, of whom 2113 underwent repair of a primary ven